
|Articles|March 1, 2001
- Pharmaceutical Executive-03-01-2001
- Volume 0
- Issue 0
Surrounded
Author(s)Wayne Koberstein
}Drug costs continue to rise at an alarming rate. Two major reasons for the increasing costs are introductions of new drugs and direct-to-consumer advertising campaigns that have been effective in marketing expensive name brand drugs.}
Advertisement
Articles in this issue
over 24 years ago
Research: New Horizonsover 24 years ago
Earnings: Tough Times Aheadover 24 years ago
Outbreak: Anthrax Alarmover 24 years ago
Patents: China on the Genome Mapover 24 years ago
Privacy, Pediatrics, and Policyover 24 years ago
Lilly's International Familyover 24 years ago
Update: Punishment and Reprieveover 24 years ago
Shortage: Vaccine Worriesover 24 years ago
Gateway to JapanNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Thermo Fisher Enters $8.8 Billion Definitive Agreement to Acquire Clario Holdings
2
What Impact will DTC Programs have on Generic Drug Prices?
3
What Impact will FDA's ANDA Prioritization Pilot have on the Global Supply Chain?
4
FDA Approves Single-Injection, Once-Monthly Maintenance Regimen for Lilly’s Omvoh in Ulcerative Colitis
5





